Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative
Tarlock K, Hansen M, Hylkema T, Ries R, Farrar J, Auvil J, Gerhard D, Smith M, Davidsen T, Gesuwan P, Hermida L, Marra M, Mungall A, Mungall K, Ma Y, Zong S, Long W, Boggon T, Alonzo T, Kolb E, Gamis A, Meshinchi S. Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative. Blood 2015, 126: 87. DOI: 10.1182/blood.v126.23.87.87.Peer-Reviewed Original ResearchFLT3/ITDChildren's Oncology GroupFLT3 mutationsOncology GroupPediatric cohortPediatric AMLFLT3 geneActivating mutationsTyrosine kinase domainAcute myeloid leukemiaDe novo resistanceInternal tandem duplicationJuxtamembrane domainCommon activating mutationsCo-occurring mutationsTargeted exome captureResistance conferring mutationsCOG trialsChildhood AMLUnnecessary toxicityInhibitor exposureFLT3 inhibitionNovo resistanceAdult studiesExcessive activation